Aware Super Pty Ltd as trustee of Aware Super Purchases 15,454 Shares of IDEXX Laboratories, Inc. $IDXX

Key Points

• Aware Super increased its IDEXX Laboratories stake by 26.1% in the third quarter, purchasing 15,454 shares to own 74,577 shares valued at approximately $38.9 million. Institutional investors collectively hold 87.84% of the company.
• IDEXX reported quarterly earnings of $3.96 per share and revenue of $1.21 billion, beating analyst estimates, while revenue grew 9.9% year over year. Recurring diagnostic revenue rose about 11%, and management raised its full-year 2026 earnings and revenue guidance.
• Analysts maintain a “Moderate Buy” consensus rating with an average price target of $721.67, though risks include softer veterinary visit volumes, potential margin pressure and the stock’s premium valuation.

Aware Super Pty Ltd as trustee of Aware Super boosted its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 26.1% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 74,577 shares of the company's stock after purchasing an additional 15,454 shares during the period. Aware Super Pty Ltd as trustee of Aware Super owned 0.09% of IDEXX Laboratories worth $38,943,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. J.Safra Asset Management Corp purchased a new stake in shares of IDEXX Laboratories during the 2nd quarter worth about $25,000. Elevation Wealth Partners LLC increased its holdings in IDEXX Laboratories by 188.2% in the second quarter. Elevation Wealth Partners LLC now owns 49 shares of the company's stock worth $26,000 after buying an additional 32 shares during the last quarter. Pension & Wealth Management Advisors Inc. acquired a new position in IDEXX Laboratories in the third quarter worth approximately $29,000. Arlington Trust Co LLC raised its position in IDEXX Laboratories by 46.3% during the second quarter. Arlington Trust Co LLC now owns 60 shares of the company's stock valued at $32,000 after acquiring an additional 19 shares in the last quarter. Finally, Bell Investment Advisors Inc raised its position in IDEXX Laboratories by 45.5% during the third quarter. Bell Investment Advisors Inc now owns 64 shares of the company's stock valued at $33,000 after acquiring an additional 20 shares in the last quarter. Hedge funds and other institutional investors own 87.84% of the company's stock.

Insiders Place Their Bets

In other IDEXX Laboratories news, Director Lawrence D. Kingsley sold 2,203 shares of the company's stock in a transaction dated Friday, September 4th. The shares were sold at an average price of $532.08, for a total transaction of $1,172,172.24. Following the completion of the sale, the director directly owned 9,568 shares in the company, valued at $5,090,941.44. This represents a 18.72% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.79% of the stock is currently owned by corporate insiders.

IDEXX Laboratories Price Performance

Shares of IDEXX Laboratories stock opened at $671.64 on Tuesday. The company has a current ratio of 1.17, a quick ratio of 0.87 and a debt-to-equity ratio of 0.19. The firm has a fifty day simple moving average of $536.56 and a 200-day simple moving average of $573.88. The stock has a market capitalization of $52.91 billion, a price-to-earnings ratio of 39.59 and a beta of 1.55. IDEXX Laboratories, Inc. has a 1-year low of $500.61 and a 1-year high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last posted its earnings results on Monday, November 2nd. The company reported $3.96 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.71 by $0.25. The business had revenue of $1.21 billion for the quarter, compared to analyst estimates of $1.19 billion. IDEXX Laboratories had a net margin of 25.03% and a return on equity of 71.96%. IDEXX Laboratories's revenue was up 9.9% compared to the same quarter last year. During the same period last year, the business posted $3.22 EPS. On average, sell-side analysts expect that IDEXX Laboratories, Inc. will post 14.81 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research firms have issued reports on IDXX. Weiss Ratings upgraded shares of IDEXX Laboratories from a "hold (c)" rating to a "hold (c+)" rating in a research note on Thursday, October 8th. Barclays decreased their target price on shares of IDEXX Laboratories from $800.00 to $710.00 and set an "overweight" rating for the company in a research report on Tuesday, August 11th. The Goldman Sachs Group assumed coverage on shares of IDEXX Laboratories in a research note on Friday, October 16th. They set a "buy" rating and a $740.00 price target on the stock. Citigroup raised their price target on shares of IDEXX Laboratories from $650.00 to $670.00 and gave the company a "neutral" rating in a report on Wednesday, August 5th. Finally, UBS Group reduced their price objective on shares of IDEXX Laboratories from $670.00 to $627.00 and set a "neutral" rating for the company in a research note on Tuesday, October 27th. Eight equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company's stock. According to MarketBeat.com, IDEXX Laboratories currently has an average rating of "Moderate Buy" and a consensus target price of $721.67.

Key Stories Impacting IDEXX Laboratories

Here are the key news stories impacting IDEXX Laboratories this week:

• Positive Sentiment: Q3 earnings and revenue beat estimates. IDEXX reported adjusted earnings of approximately $3.96–$3.98 per share versus the $3.71 consensus estimate. Revenue rose about 10% year over year to $1.21 billion, exceeding expectations of roughly $1.19 billion. IDEXX Laboratories Q3 earnings report
• Positive Sentiment: Recurring diagnostics remained the key growth engine. Recurring diagnostic revenue to veterinarians increased about 11%, demonstrating continued demand for IDEXX’s testing platforms and supporting the company’s earnings growth despite softer veterinary visit trends. IDEXX raises forecast
• Positive Sentiment: Management raised its full-year 2026 earnings and revenue guidance. The revised outlook suggests that IDEXX expects diagnostics growth, operating performance and customer adoption of its offerings to offset weakness in veterinary visit volumes. The guidance increase was the primary catalyst behind the strong stock reaction. IDEXX revises 2026 earnings guidance
• Neutral Sentiment: The earnings call reinforced a favorable long-term growth narrative. Management highlighted continued expansion in diagnostics, recurring revenue and productivity initiatives, which may support durable growth but also leaves the stock reliant on sustained premium valuation expectations. IDEXX Laboratories earnings call highlights
• Negative Sentiment: Margin trends and veterinary demand remain risks. Some reports noted that the higher profit forecast was not driven by stronger testing demand, while the margin outlook softened. Weak veterinary visits could pressure near-term volume growth if diagnostics expansion does not continue. IDEXX sales and margin outlook

About IDEXX Laboratories

IDEXX Laboratories, Inc NASDAQ: IDXX develops and provides diagnostic, information technology, and related products and services for the animal health and water testing markets. The company primarily serves veterinary practices, helping them diagnose and monitor diseases through laboratory tests, in-clinic analyzers, software, and digital practice-management solutions.

IDEXX's companion animal offerings include hematology, chemistry, urinalysis, immunodiagnostics, and imaging-related products, along with reference laboratory services and veterinary software.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.